Merck (MRK) stock
NYSE
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $362.5B
- As of Nov 5, 2026
- P/E
- 114.25x
- Trailing twelve months
- P/B
- 8.64x
- Latest reported equity
- P/S
- 5.45x
- Trailing twelve months
- ROE
- 7.6%
- Trailing twelve months
- Dividend yield
- 2.23%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $362.5B
- As of Nov 5, 2026
- P/E
- 114.25x
- Trailing twelve months
- P/B
- 8.64x
- Latest reported equity
- P/S
- 5.45x
- Trailing twelve months
- ROE
- 7.6%
- Trailing twelve months
- Dividend yield
- 2.23%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
114.25x
P/B
8.64x
P/S
5.45x
Earnings and dividend metrics▾
Earnings
EPS
$1.29
Earnings per share
BPS
$17.00
Book value per share
ROE
7.6%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $1.29 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $17.00 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 7.6%.
Dividends
Yield
2.23%
Dividend per share
$3.28
Payout ratio
257.7%
Consecutive years
19+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $328.00 before tax.
- Payout ratio — 257.7% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 19 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 4.7% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Based on the company earnings press release. These figures come before the periodic report and may include adjusted measures.
Revenue · same quarter, three years
Year-ago quarter $17.3B+4.7%
From the company press release attached to an 8-K earnings filing. These figures come before the periodic report (10-Q or 10-K) and may include adjusted (non-GAAP) measures.
$16.7B
Jul–Sep '24
$17.3B
Jul–Sep '25
$18.1B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 come from the company press release attached to an 8-K earnings filing submitted to SEC EDGAR on Oct 29, 2026.
- Press release figures come before the periodic report (10-Q or 10-K) and may include adjusted (non-GAAP) measures, so they can differ from later filings.
- Earnings per share decreased 12.1% from the same quarter a year earlier.
- Revenue increased 4.7% from the same quarter a year earlier.
- Net income decreased 12.4% from the same quarter a year earlier.
Filed Oct 29, 2026 · 8-K · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Korean AI analysis available →Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Guindo ChirfiEVP, Access, Policy & Comms · Aug 13, 2026Open-market sale10,000 shares · $1.4MAvg. price $13536,613 shares held after
- Zachary JenniferEVP, General Counsel · Aug 12, 2026Open-market sale80,315 shares · $10.7MAvg. price $133.455745,509 shares held after
- DeLuca Richard R.EVP&Pres, Merck Animal Heallth · Aug 12, 2026Open-market sale11,699 shares · $1.5MAvg. price $131.6345
Show 2 price lots
- 11,099 shares × $131.6128$1.5M
- 600 shares × $132.0367$79K
- Zachary JenniferEVP, General Counsel · Aug 12, 2026Option exercise54,927 shares · $6.0MAvg. price $109.7755
Show 2 price lots
- 41,494 shares × $117.89$4.9M
- 13,433 shares × $84.71$1.1M
- DeLuca Richard R.EVP&Pres, Merck Animal Heallth · Aug 11, 2026Open-market sale12,837 shares · $1.7MAvg. price $131.7618
Show 2 price lots
- 7,410 shares × $131.3313$973K
- 5,427 shares × $132.3496$718K
- DeLuca Richard R.EVP&Pres, Merck Animal Heallth · Aug 10, 2026Open-market sale20,784 shares · $2.7MAvg. price $130.4345134,703 shares held after
- Guindo ChirfiEVP, Access, Policy & Comms · Aug 6, 2026Open-market sale15,000 shares · $2.0MAvg. price $13146,613 shares held after
- DeLuca Richard R.EVP&Pres, Merck Animal Heallth · Aug 6, 2026Open-market sale6,050 shares · $789KAvg. price $130.3756
Show 3 price lots
- 4,945 shares × $130.2312$644K
- 805 shares × $131.0216$105K
- 300 shares × $131.0233$39K
- Williams David MichaelEVP,Chief Info&Digital Officer · Aug 5, 2026Open-market sale52,847 shares · $6.8MAvg. price $128.770731,716 shares held after
Show 3 price lots
- 34,705 shares × $128.7707$4.5M
- 13,542 shares × $128.7707$1.7M
- 4,600 shares × $128.7707$592K
- Maraldo David R.EVP & Pres. MMD · Aug 5, 2026Open-market sale18,706 shares · $2.4MAvg. price $128.717918,212 shares held after
Show 3 price lots
- 9,709 shares × $128.7179$1.2M
- 6,311 shares × $128.7179$812K
- 2,686 shares × $128.7179$346K
- Williams David MichaelEVP,Chief Info&Digital Officer · Aug 5, 2026Option exercise52,847 shares · $3.9MAvg. price $74.4863
Show 3 price lots
- 34,705 shares × $73.73$2.6M
- 13,542 shares × $75.36$1.0M
- 4,600 shares × $77.62$357K
- Maraldo David R.EVP & Pres. MMD · Aug 5, 2026Option exercise18,706 shares · $1.5MAvg. price $82.2461
Show 3 price lots
- 9,709 shares × $87.1$846K
- 6,311 shares × $73.73$465K
- 2,686 shares × $84.71$228K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said global sales were $18.1 billion in Q3 2026, and U.S. sales were $51.0 billion in January–September, each up 5% from the year-earlier period. It said the oncology, cardiometabolic, respiratory and specialty franchises and animal health were the main drivers, while the vaccines and infectious diseases franchise declined.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KMerck said worldwide sales for Q3 2026 were $18,085 million, up 5% from a year earlier (4% excluding foreign exchange). Sales of KEYTRUDA/KEYTRUDA QLEX rose 6% to $8,601 million, of which KEYTRUDA QLEX accounted for $830 million.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KThe company said on October 13, 2026 that it had announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. The company said he will stand for election by shareholders in May 2027.Published Oct 13, 2026 · Filed Oct 13, 2026Read the summary →
- The company said global sales were $18.1 billion in Q3 2026, and U.S. sales were $51.0 billion in January–September, each up 5% from the year-earlier period. It said the oncology, cardiometabolic, respiratory and specialty franchises and animal health were the main drivers, while the vaccines and infectious diseases franchise declined.Read the full analysis →
- Merck said worldwide sales for Q3 2026 were $18,085 million, up 5% from a year earlier (4% excluding foreign exchange). Sales of KEYTRUDA/KEYTRUDA QLEX rose 6% to $8,601 million, of which KEYTRUDA QLEX accounted for $830 million.Read the full analysis →
- The company said on October 13, 2026 that it had announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. The company said he will stand for election by shareholders in May 2027.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Merck (MRK) stock information
NYSE
Merck (MRK) is listed on NYSE. Its market capitalization is about $362.5B. On trailing-twelve-month earnings the P/E ratio is 114.25, and the P/B ratio is 8.64. Return on equity is 7.6%. These figures are computed in-house from official filings and are reference information only.
Merck — frequently asked questions
- What is the P/E ratio of Merck (MRK)?
- On a trailing-twelve-month basis, MRK trades at a P/E ratio of 114.25. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Merck?
- MRK has a market capitalization of about $362.5B. The figure moves with the share price and is refreshed each trading day.
- Does Merck pay a dividend?
- MRK has a dividend yield of about 2.23%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.